Bleeding and stent thrombosis on P2Y12-inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention.
about
Personalized antiplatelet therapy with P2Y12 receptor inhibitors: benefits and pitfallsPlatelet turnover predicts outcome after coronary intervention.Major bleeding events in Jordanian patients undergoing percutaneous coronary intervention (PCI): Incidence, associated factors, impact on prognosis, and predictability of the CRUSADE bleeding risk score. Results from the First Jordanian PCR (PCR1)Genomewide Association Study Identifies Novel Genetic Loci That Modify Antiplatelet Effects and Pharmacokinetics of ClopidogrelPlatelet aggregation and risk of stent thrombosis or bleeding in interventionally treated diabetic patients with acute coronary syndrome.Cell-Penetrating Pepducin Therapy Targeting PAR1 in Subjects With Coronary Artery Disease.Impact of Cytochrome P450 2C19*2 and *3 on Clopidogrel Loading Dose in Saudi Patients with Acute Coronary Syndrome.Relationship of Platelet Reactivity With Bleeding Outcomes During Long-Term Treatment With Dual Antiplatelet Therapy for Medically Managed Patients With Non-ST-Segment Elevation Acute Coronary SyndromesPre-treatment with P2Y12 inhibitors in ACS patients: who, when, why, and which agent?Novel strategies for assessing platelet reactivity.First report of the point-of-care TEG: A technical validation study of the TEG-6S system.Comparison of Ticagrelor Pharmacokinetics and Pharmacodynamics in STEMI and NSTEMI Patients (PINPOINT): protocol for a prospective, observational, single-centre study.Platelet function testing as a biomarker for efficacy of antiplatelet drugs.Validation of Three Platelet Function Tests for Bleeding Risk Stratification During Dual Antiplatelet Therapy Following Coronary Interventions.Personalizing antiplatelet therapies: What have we learned from recent trials?Management of antithrombotic therapy after bleeding in patients with coronary artery disease and/or atrial fibrillation: expert consensus paper of the European Society of Cardiology Working Group on Thrombosis.CRUSADE Score is Superior to Platelet Function Testing for Prediction of Bleeding in Patients Following Coronary Interventions.Low On-Treatment Platelet Reactivity Predicts Long-Term Risk of Bleeding After Elective PCI.Stent Thrombosis Patients with Hyporesponsiveness to Clopidogrel, Prasugrel, and Ticagrelor: A Case Series Using Short Thromboelastography.Comparison of bioavailability and antiplatelet action of ticagrelor in patients with ST-elevation myocardial infarction and non-ST-elevation myocardial infarction: A prospective, observational, single-centre study.Abciximab as a bridging strategy to overcome morphine-prasugrel interaction in STEMI patients.Comment on "Prospective study to evaluate safety and efficacy of Zotarolimus Eluting Stent (PSEZES) in patients with long coronary artery lesions".Temporary Stent-Assisted Coil Embolization as a Treatment Option for Wide-Neck Aneurysms.Long-term pharmacodynamic effects of Ticagrelor versus Clopidogrel in fibrinolytic-treated STEMI patients undergoing early PCI.Effects of genetic variants on platelet reactivity and one-year clinical outcomes after percutaneous coronary intervention: A prospective multicentre registry study.Antiplatelet Therapy in ACS Patients: Comparing Appropriate P2Y12 Inhibition by Clopidogrel to the Use of New P2Y12 Inhibitors.Determinants of agreement between proposed therapeutic windows of platelet function tests in vulnerable patients.2017 EACTS Guidelines on perioperative medication in adult cardiac surgery.Impact of Test Conditions on ADP-Induced Platelet Function Results With the Multiplate Assay: Is Further Standardization Required?2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS.Platelet reactivity-adjusted antiplatelet therapy in patients with percutaneous coronary intervention: a meta-analysis of randomized controlled trials.Platelet reactivity over time in coronary artery disease patients treated with a bioabsorbable everolimus-eluting scaffold.Genome-wide and candidate gene approaches of clopidogrel efficacy using pharmacodynamic and clinical end points-Rationale and design of the International Clopidogrel Pharmacogenomics Consortium (ICPC).Clinical implementation of rapid CYP2C19 genotyping to guide antiplatelet therapy after percutaneous coronary intervention.Ticagrelor versus prasugrel in patients with high on-clopidogrel treatment platelet reactivity after PCI: The ISAR-ADAPT-PF study.Syncope and sudden cardiac death: some answers to clinical challenges.Prognostic value of high on-treatment platelet reactivity.De-Escalation of P2Y12 Receptor Inhibitor Therapy after Acute Coronary Syndromes in Patients Undergoing Percutaneous Coronary Intervention2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTSImpact of Obstructive Sleep Apnea on Platelet Function Profiles in Patients With Acute Coronary Syndrome Taking Dual Antiplatelet Therapy
P2860
Q26775125-7CB0BBF6-03C2-40E8-BD16-A5EAD771E703Q33721709-CD58FC31-D2A6-4221-89A1-39B97C5C558EQ33814243-802F3B92-166B-4D7D-9BEB-C83C1AD31626Q33837665-B2E29858-3119-4DA4-8AC6-8B91FC3B9984Q36216424-B95FC9A8-B67E-4C90-83B1-B88190457F42Q36813106-478902CC-8958-4326-A3D7-0D3DE833B341Q37203987-7DAAC01C-1A47-4F7B-9DB8-5E78DCBB8414Q37556037-AD2A1E97-6BA2-4B0A-ACF1-5FAD39F21B7FQ38682012-6194638B-8045-48D4-87D0-4BCD9E413600Q38780997-DDC6E737-ACA4-4E90-8E7D-9D412ED9F3F2Q38799118-4080A5F4-601C-49A2-95BD-FBCF95DDE503Q38818086-156B36B2-2757-4EA5-8ABE-D1E3A93D5624Q38842001-59C7EFEC-EB79-4741-B253-6A6BE96BFF7CQ38847255-F3018C9A-86F2-4F13-9972-7254717C6F26Q39382840-894E2389-D236-41EF-AB10-5A45B60D1A9FQ40478828-9A29A29D-CFB8-45DF-A946-447185B18F98Q41040676-F078BB10-FA7F-4A29-AB37-95C46DCDFAC1Q41069868-62E5EB4C-DA80-4FD9-9563-24DE682CF341Q41540603-4F276A1F-B634-47FD-A0B5-3D6CE3D49E08Q42375730-1FB60109-6D90-4B83-BC3C-42257CF582B1Q42700913-3A2CD3CC-CC11-461F-B2E7-74575B13B6E7Q43106797-F6E9B1C7-D5F3-4A5F-B4F8-65DC1280FA07Q47379551-2C1B915D-323C-40FC-AEB8-2B9F98E40594Q47420896-1615AFF0-94A8-46C0-B55D-C9AA7A627B81Q48204482-DD30BAA6-858B-4442-BB39-A7CB8E753419Q48507719-053458DB-8850-44FB-BC37-5307F42932D9Q49058595-4D7EE224-6B77-4AA8-B927-E6EE8F0D7542Q50065204-EDF5144B-2B36-4E7E-BD7C-FC9C58A09CF4Q50073758-79919CEE-17E4-4D6A-9FB1-A17F3315DEA2Q50089557-0D3ECCBA-4528-4CD1-94BA-389793AED998Q50140654-DF5FEBC9-2891-4FE1-8C4B-40916BB0E74CQ51306353-6652FC9B-3176-4F97-927E-CC30ECEF124DQ52589473-91F2D38D-D871-4C18-B0A4-8CCB32E3ADD1Q52593402-58C77E65-FF2C-4783-A084-A4B96D97F401Q53084647-ADABBD72-7154-4D68-9A34-7C651A7C8ED6Q54444751-52410EBB-6854-453D-BD63-1935BC3E1BA4Q55384520-91E0FD20-EC8E-4A06-9C8C-426D5E749B06Q57143053-CA7CDD13-59FC-4F7A-96C2-1295062C956FQ57621041-E84278DC-38AF-4A61-9921-B33C679D8D80Q58129990-59D81F17-BA53-4996-9C8D-EA44EBEA7046
P2860
Bleeding and stent thrombosis on P2Y12-inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Bleeding and stent thrombosis ...... taneous coronary intervention.
@ast
Bleeding and stent thrombosis ...... taneous coronary intervention.
@en
type
label
Bleeding and stent thrombosis ...... taneous coronary intervention.
@ast
Bleeding and stent thrombosis ...... taneous coronary intervention.
@en
prefLabel
Bleeding and stent thrombosis ...... taneous coronary intervention.
@ast
Bleeding and stent thrombosis ...... taneous coronary intervention.
@en
P2093
P50
P356
P1476
Bleeding and stent thrombosis ...... taneous coronary intervention.
@en
P2093
Dirk Sibbing
Dominick J Angiolillo
Dániel Aradi
Gregg W Stone
Jurrien ten Berg
Kurt Huber
Laurent Bonello
Matthew J Price
Matthias K Freynhofer
Olivier Morel
P304
P356
10.1093/EURHEARTJ/EHV104
P50
P577
2015-04-20T00:00:00Z